PE-22-28 (10mg Vial) Dosage Protocol

PE-22-28 (10 mg Vial) Dosage Protocol

Quickstart Highlights

PE-22-28 is a synthetic heptapeptide (sequence: GVSWGLR) derived from the sortilin propeptide, engineered as a potent and selective antagonist of TREK-1 potassium channels[4]. Preclinical studies demonstrate rapid antidepressant-like effects, enhanced neurogenesis, and neuroprotection with a favorable safety profile showing no cardiac or metabolic side effects[2][3]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • Typical daily range: 50–200 µg once daily (gradual titration over 8–16 weeks).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.
PE-22-28 Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (µg) Units (per injection) (mL)
Weeks 1–2 50 µg 1.5 units (0.015 mL)
Weeks 3–4 100 µg 3 units (0.03 mL)
Weeks 5–8 100 µg 3 units (0.03 mL)
Weeks 9–12 (Optional) 150 µg 4.5 units (0.045 mL)
Weeks 13–16 (Optional) 200 µg 6 units (0.06 mL)

Frequency: Inject once daily subcutaneously. This schedule uses a practical 3.0 mL dilution for accurate measurement. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Many researchers find 100–150 µg sufficient given PE-22-28’s high potency[4].

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration. Replace vials every 4 weeks to maintain potency.

  • Peptide Vials (PE-22-28, 10 mg each):

    • 8 weeks ≈ 2 vials
    • 12 weeks ≈ 3 vials
    • 16 weeks ≈ 4 vials
  • Insulin Syringes (U-100):

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

    • 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
    • 16 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
PE-22-28 Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support rapid neuroplasticity, mood regulation, and neuroprotection through selective TREK-1 inhibition[2][4].
  • Schedule: Daily subcutaneous injections for 12–16 weeks (8 weeks minimum).
  • Dose Range: 50–200 µg daily with conservative titration; many find 100–150 µg adequate.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for precise low-volume measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; replace vials every 4 weeks.

Dosing Protocol

Suggested conservative daily titration approach.

  • Start: 50 µg daily for Weeks 1–2 to assess tolerance.
  • Increase: 100 µg daily for Weeks 3–8 (standard maintenance dose).
  • Optional Titration: 150 µg (Weeks 9–12) or 200 µg (Weeks 13–16) only if well-tolerated and additional effect desired.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 12–16 weeks; 8 weeks minimum.
  • Timing: Consistent daily time; rotate injection sites systematically.

Storage Instructions

Proper storage preserves peptide quality and potency.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks for optimal potency.
  • Allow vials to reach room temperature before opening to reduce condensation; protect from light.
  • Replace with fresh vial every 4 weeks even if peptide remains; bacteriostatic water sterility is guaranteed for 28 days after first puncture[10].

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container immediately.
  • Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle to prevent leakage.
  • Document daily dose, site rotation, and any observations to maintain protocol consistency.
  • Given PE-22-28’s high potency (IC50 ~0.12 nM), conservative dosing is recommended; most preclinical effects occurred at low microgram ranges[4].

How This Works

PE-22-28 functions as a potent and selective antagonist of TREK-1 (KCNK2) two-pore domain potassium channels[2]. By blocking TREK-1, it depolarizes neurons and enhances excitability, leading to increased firing of serotonergic neurons and elevated monoamine neurotransmission[2]. This mechanism produces rapid antidepressant-like effects in preclinical models—within 4 days, PE-22-28 significantly increases hippocampal neurogenesis and synaptogenesis markers, changes typically requiring weeks with conventional antidepressants[4]. The peptide also activates CaMKII/CREB pathways that promote neuronal survival and plasticity[6]. PE-22-28 represents a shortened, optimized analog of spadin with superior potency (IC50 ~0.12 nM versus 40–60 nM for spadin) and longer duration of action (~23 hours versus ~7 hours)[4]. Notably, research also demonstrates neuroprotective effects in stroke models through biphasic dosing that leverages both TREK-1 activation at ultra-low doses and inhibition at standard doses[5].

Potential Benefits & Observed Safety Profile

Observations from preclinical literature and mechanistic studies.

  • Rapid Antidepressant Effects: Produces behavioral improvements within 4 days in rodent models; reduces immobility in forced swim tests and decreases latency to feed in novel environments[4].
  • Enhanced Neuroplasticity: Increases hippocampal neurogenesis, synaptogenesis markers (PSD-95), dendritic spine density, and BDNF expression within days[4].
  • Neuroprotection: In stroke models, preserves dopaminergic neurons, reduces motor deficits, and prevents post-stroke depressive behavior[5].
  • Favorable Safety Profile: Shows high selectivity with no effects on hERG channels (cardiac safety), no impact on heart rate, blood pressure, glucose regulation, or pain perception in preclinical studies[3]. No TREK-1-related side effects or withdrawal observed[3].
  • No Human Data: All evidence is from cell culture and animal studies; human safety and pharmacokinetics remain unestablished[1].
  • Potential Mild Reactions: Subcutaneous administration may occasionally cause minor injection-site reactions (slight redness or tenderness).

Lifestyle Factors

Complementary strategies to support neuroplasticity and mood optimization.

  • Maintain consistent sleep schedule and prioritize 7–9 hours of quality sleep to support neurogenesis.
  • Engage in regular physical activity; both aerobic exercise and resistance training enhance BDNF and mood-regulating pathways.
  • Follow a nutrient-dense diet rich in omega-3 fatty acids, antioxidants, and B-vitamins to support brain health.
  • Practice stress-management techniques (meditation, mindfulness, therapy) to complement neuroplastic adaptations.
  • Consider cognitive training or novel learning activities to synergize with enhanced synaptic plasticity.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

  • Clean the vial stopper and injection site with alcohol; allow both to air-dry completely[8][9].
  • Pinch a skinfold of subcutaneous tissue; insert the needle at 45° (or 90° if using very short needles with ample subcutaneous fat)[8].
  • Do not aspirate for subcutaneous injections; inject solution slowly and steadily[8].
  • Rotate sites systematically (abdomen at least 2 inches from navel, front/outer thighs, outer upper arms) to prevent lipohypertrophy and maintain absorption consistency[9].
  • Given the very small injection volumes (often ≤0.10 mL), technique precision is critical. Consider using 30- or 50-unit insulin syringes for doses under 10 units to improve measurement accuracy.
  • Withdraw needle at the same angle inserted; apply gentle pressure if needed; dispose of syringe immediately in sharps container.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. PE-22-28 is a research peptide not FDA-approved for human use. All information is derived from preclinical studies; no human clinical trials have been published. Consult qualified healthcare professionals before considering any experimental compounds.

References


  • Pure Lab Peptides
    — PE-22-28 (10 mg) product page (research-grade peptide, quality documentation)
    View Source

  • PLoS Biology (2010)
    — Mazella et al.: Spadin, a sortilin-derived peptide targeting TREK-1 channels; novel antidepressant mechanism
    View Source

  • Neuropharmacology (2012)
    — Moha Ou Maati et al.: Spadin as antidepressant; absence of TREK-1-related side effects
    View Source

  • Frontiers in Pharmacology (2017)
    — Djillani et al.: Shortened spadin analogs (PE-22-28); superior TREK-1 inhibition, in vivo stability, antidepressant activity
    View Source

  • Neuropharmacology (2019)
    — Pietri et al.: Protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides
    View Source

  • Pharmacological Research (2021)
    — Daziano et al.: Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway
    View Source

  • International Journal of Molecular Sciences (2022)
    — Chang et al.: Potential of heterogeneous compounds as antidepressants; narrative review including TREK-1 modulators
    View Source

  • CDC
    — Vaccine administration: subcutaneous injection instruction guide (technique, angle, no aspiration)
    View Source

  • CDC
    — 4 Ways to Take Insulin; section on injection site rotation and subcutaneous technique
    View Source

  • CDC Pink Book
    — General best practice guidelines: vaccine administration; multi-dose vial 28-day sterility rule
    View Source